Cargando…

Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats

Background: Naoxintong Capsule (NXT) is a formulated Traditional Chinese Medicine (TCM) widely applied in the treatment of cardiovascular and metabolic diseases, most of which are closely related to hyperlipidemia as a major risk factor. Given the current limited understandings to the role of gut mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yihang, Wan, Haofang, Wu, Yujia, Yang, Jiehong, Yu, Li, He, Yu, Wan, Haitong, Li, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978017/
https://www.ncbi.nlm.nih.gov/pubmed/35387330
http://dx.doi.org/10.3389/fphar.2022.843409
_version_ 1784680891286552576
author Lu, Yihang
Wan, Haofang
Wu, Yujia
Yang, Jiehong
Yu, Li
He, Yu
Wan, Haitong
Li, Chang
author_facet Lu, Yihang
Wan, Haofang
Wu, Yujia
Yang, Jiehong
Yu, Li
He, Yu
Wan, Haitong
Li, Chang
author_sort Lu, Yihang
collection PubMed
description Background: Naoxintong Capsule (NXT) is a formulated Traditional Chinese Medicine (TCM) widely applied in the treatment of cardiovascular and metabolic diseases, most of which are closely related to hyperlipidemia as a major risk factor. Given the current limited understandings to the role of gut microbiota in the lipid-lowering effect of NXT and other TCM products, this study investigated the regulation of gut microbiota and lipid metabolism by NXT, and their potential relationship. Methods: The chemical components of NXT were firstly analyzed with HPLC-MS method. In high fat diet (HFD)-fed rat models, as well as normal rats as control, the histopathological and biochemical changes of serum and liver were examined, including total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C). In addition, the gut microbiota community was analyzed using 16S rRNA sequencing technique, the fecal levels of gut microbiota related metabolites, including bile acids (BAs) and short chain fatty acids (SCFAs) were determined with HPLC-MS. The correlations of the clinical indicators and gut microbiota related indicators were then investigated statistically. Results: The results showed that NXT exerted potential preventive effect on hyperlipidemia. Specifically, NXT significantly reduced the body weight, TC, TG and LDL-C in serum, increased HDL-C in serum, reduced the TC and TG in liver, as well as protected liver. The body weight, serum lipid levels and liver function were all significantly alleviated. The gut microbiota of the HFD-fed rats was reconstituted with supplementation of NXT. The fecal levels of gut microbiota related metabolites, including BAs and SCFAs were also altered. The correlation between the gut microbiota and clinical/metabolomic parameters was then studied. As the result, the amount of propionic aicd, Firmicutes/Bacteroidetes ratio (F/B) and the relative abundance of Collinsella in feces are the most possibly potential therapeutic biomarkers of NXT. Conclusion: NXT was effective in regulation of gut microbiota and prevention of hyperlipidemia in HFD fed rats. The present work might provide novel insights into the anti-hyperlipidemia effect of TCM and afford new scientific evidence for clinical application of TCM.
format Online
Article
Text
id pubmed-8978017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89780172022-04-05 Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats Lu, Yihang Wan, Haofang Wu, Yujia Yang, Jiehong Yu, Li He, Yu Wan, Haitong Li, Chang Front Pharmacol Pharmacology Background: Naoxintong Capsule (NXT) is a formulated Traditional Chinese Medicine (TCM) widely applied in the treatment of cardiovascular and metabolic diseases, most of which are closely related to hyperlipidemia as a major risk factor. Given the current limited understandings to the role of gut microbiota in the lipid-lowering effect of NXT and other TCM products, this study investigated the regulation of gut microbiota and lipid metabolism by NXT, and their potential relationship. Methods: The chemical components of NXT were firstly analyzed with HPLC-MS method. In high fat diet (HFD)-fed rat models, as well as normal rats as control, the histopathological and biochemical changes of serum and liver were examined, including total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C). In addition, the gut microbiota community was analyzed using 16S rRNA sequencing technique, the fecal levels of gut microbiota related metabolites, including bile acids (BAs) and short chain fatty acids (SCFAs) were determined with HPLC-MS. The correlations of the clinical indicators and gut microbiota related indicators were then investigated statistically. Results: The results showed that NXT exerted potential preventive effect on hyperlipidemia. Specifically, NXT significantly reduced the body weight, TC, TG and LDL-C in serum, increased HDL-C in serum, reduced the TC and TG in liver, as well as protected liver. The body weight, serum lipid levels and liver function were all significantly alleviated. The gut microbiota of the HFD-fed rats was reconstituted with supplementation of NXT. The fecal levels of gut microbiota related metabolites, including BAs and SCFAs were also altered. The correlation between the gut microbiota and clinical/metabolomic parameters was then studied. As the result, the amount of propionic aicd, Firmicutes/Bacteroidetes ratio (F/B) and the relative abundance of Collinsella in feces are the most possibly potential therapeutic biomarkers of NXT. Conclusion: NXT was effective in regulation of gut microbiota and prevention of hyperlipidemia in HFD fed rats. The present work might provide novel insights into the anti-hyperlipidemia effect of TCM and afford new scientific evidence for clinical application of TCM. Frontiers Media S.A. 2022-03-21 /pmc/articles/PMC8978017/ /pubmed/35387330 http://dx.doi.org/10.3389/fphar.2022.843409 Text en Copyright © 2022 Lu, Wan, Wu, Yang, Yu, He, Wan and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lu, Yihang
Wan, Haofang
Wu, Yujia
Yang, Jiehong
Yu, Li
He, Yu
Wan, Haitong
Li, Chang
Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title_full Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title_fullStr Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title_full_unstemmed Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title_short Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats
title_sort naoxintong capsule alternates gut microbiota and prevents hyperlipidemia in high-fat-diet fed rats
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978017/
https://www.ncbi.nlm.nih.gov/pubmed/35387330
http://dx.doi.org/10.3389/fphar.2022.843409
work_keys_str_mv AT luyihang naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT wanhaofang naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT wuyujia naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT yangjiehong naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT yuli naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT heyu naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT wanhaitong naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats
AT lichang naoxintongcapsulealternatesgutmicrobiotaandpreventshyperlipidemiainhighfatdietfedrats